



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07K 14/52, A61K 38/19, A61P 37/00		A2	(11) International Publication Number: WO 00/27880
			(43) International Publication Date: 18 May 2000 (18.05.00)
(21) International Application Number: PCT/EP99/08651		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 11 November 1999 (11.11.99)		Published Without international search report and to be republished upon receipt of that report.	
(30) Priority Data: MI98A002441 11 November 1998 (11.11.98) IT			
(71) Applicants (for all designated States except US): FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR [IT/IT]; Via Olgettina, 60, I-20132 Milano (IT). PRIMM S.R.L. [IT/IT]; Via Olgettina, 58, I-20132 Milano (IT).			
(72) Inventors; and (75) Inventors/Applicants (for US only): LUSSO, Paolo [IT/IT]; Via Olgettina, 58, I-20132 Milano (IT). PAVONE, Vincenzo [IT/IT]; Viale Michelangelo, 52, I-80129 Napoli (IT).			
(74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).			
(54) Title: RANTES-DERIVED PEPTIDES WITH ANTI-HIV ACTIVITY			
(57) Abstract Peptides having 12 to 30 amino acids with sequence homologous or corresponding to the sequence 10-34 of RANTES having inhibitory activity against the human immunodeficiency virus (HIV) as well as anti-allergic and antiinflammatory activity.			

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PC

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

RANTES-DERIVED PEPTIDES WITH ANTI-HIV ACTIVITY

The present invention relates to RANTES-derived peptides having inhibitory activity against the human immunodeficiency virus (HIV).

5 The peptides of the invention are useful for the treatment of diseases which are connected with the infection of viruses like HIV-1, other primate-lentiretroviruses (HIV-2, SIV) and other viruses which use chemokine receptors to bind the cellular surface and/or to penetrate the target cell, as well as for the treatment of all the diseases, like the allergic or autoimmune
10 diseases, in the pathogenesis of which chemokines play an important role.

Background of the invention

The term chemokine is used to identify a family of chemotactic cytokines characterized by a high degree of genetic, structural and functional similarity (Immunol. Today 1993, 14:24).

15 Most known chemokines are grouped in two main families referred to as C-X-C and C-C, depending on the configuration of a conserved motif of two cysteine in their sequence (Ann. Rev. Immunol. 1994, 55:97-179).

Chemokines are important mediators of the inflammatory response which act through the recruitment of specific cellular populations of the
20 immune system in the inflammatory site; the C-X-C chemokines are generally active on neutrophil granulocytes while the C-C chemokines are active on eosinophil and basophil granulocytes, on lymphocytes and monocytes.

RANTES, MIP-1 α and MIP-1 β are C-C chemokines which have been
25 proposed as possible mediators of autoimmune and allergic diseases.

Recently, a specific antiviral effect against primate lentiretrovirus has been described for those three chemokines (Science, 1995, 270:1811-1815).

RANTES is the most potent among C-C chemokines which inhibit the

HIV infection. This chemokine bonds to the CCR5 receptor, which is the main membrane co-receptor for HIV-1, in that it is used by most viral strains present in the population and preferably sexually transmitted. Said receptor is therefore a primary target for possible therapeutical strategies, above all during the asymptomatic phase of HIV disease. However, the therapeutic use of natural chemokines is hampered by their pro-inflammatory activity, in that most chemokines are involved in leucocyte recruitment at the inflammation and infection sites, and in their functional activation.

At the moment a preliminary knowledge exists of the domains involved in the pro-inflammatory activity of some chemokines, but not of the domains involved in the antiviral activity. A number of recent studies have suggested that an element crucial for the chemokine-induced receptor activation is located at the molecule's NH₂-terminus (J. Biol. Chem. 1991; 266:23128-23134; Biochem. Biophys. Comm. 1995, 211:100-105). Actually, a preliminary study (Nature, 1996, 383:400) and a more detailed study (Science; 1997, 276-282), both recently published, have shown that RANTES-chemokine analogues modified at the NH₂ terminus (through the deletion of 8 amino acids, or through the covalent bond of a complex chemical radical [amino-oxy-pentane or AOP], respectively) maintain the anti-HIV activity even though they do not induce chemotaxis in vitro or they induce it to a very low extent.

Peptides corresponding to the sequences 7-68 to 10-68 of RANTES are disclosed in WO97/44462. RANTES mutants such as Leu-RANTES and Met-RANTES are disclosed in WO96/17935 and WO98/13495. However, in therapeutical applications, the use of small molecules or peptides is preferred, compared with the whole protein, although in the recombinant form, for a number of reasons, such as easiness of synthesis and possibility of minimizing any side-effects caused by the molecule regions which are not

useful or even harmful. A number of examples of peptides in the pre-clinical phase for anti-HIV therapy can, in fact, be found in literature: 1) Judice et al., PNAS 94:13426,1997, disclose structurally rigid peptides deriving from the gp41 sub-unit of HIV envelope, which inhibit the fusion of the cell membrane; 2) Prieto et al., AIDS Res Hum Retroviruses 12:1023,1996, disclosed modified peptides (benzyl-conjugated) deriving from CD4; or 3) Robinson et al., J Leuk Biol 63:94, 1998, disclose the activity of Indolicin 13-mer, a natural peptide of bovine origin, neutrophil and capable of inhibiting HIV virus at doses comprised from 60 to 100 μ M; 4) Heveker et al., Curr Biol 8:369, 1998: describe peptides deriving from the N-terminus of SDF-1, capable of inhibiting HIV and which also lack the pro-inflammatory activity when the first two amino acids are deleted.

Disclosure of the invention

It has now been found that RANTES-derived peptides are particularly active in inhibiting HIV viral infection.

The peptides of the invention have 12 to 30 amino acids with sequence identical to a portion of at least 5 consecutive aminoacids of the sequence 9-38 of RANTES.

The peptides of the invention consist of either natural amino acids of the D or L series or of modified or "non-protein" amino acids.

Preferably, the peptides of the invention have from 15 to 35 amino acids, more preferably from 18 to 25 amino acids.

Preferably, the peptides of the invention have a sequence derived from or identical to at least 10 consecutive amino acids of the sequence 9-38 of RANTES, more preferably derived from or identical to at least 12 amino acids and even more preferably derived from or identical to at least 15 amino acid, the other amino acids in the peptide sequence deriving from conservative substitutions of the natural amino acids in the native sequence

of RANTES.

The sequence identity of the peptides of the invention with the above mentioned RANTES regions, for example the sequence comprised between the amino acid in position 9 and the amino acid in position 38 of the RANTES native sequence, is preferably of at least 50%, preferably at least 80% and more preferably of at least 90%.

The substitutions of the natural amino acids of the native sequence are preferably of conservative type, both with other natural amino acids and with non-proteic amino acids.

10 "Conservative substitution" herein means, for example, the substitution of a hydrophobic amino acid with another hydrophobic amino acid, of a basic amino acid with another basic amino acid and so on.

"Derived from" means that the native sequence may be further modified by substituting the natural amino acid with the corresponding amino acid of the D series or with non-protein amino acid and/or by inverting the sequence from the carboxy-terminus to the N-terminus and/or by forming dimers through cysteine disulfide bonds and/or by single deletion of amino acids of the native sequence. The invention also refers to peptides having two or more of the above characteristics sequences or domains linked by a suitable linker, e.g. an hydrophilic linker or a metabolic resistant linker. Said derivatives are obtainable according to known methods and criteria.

The invention also provides derivatives of said peptides, chemically modified in order to increase their in vivo stability.

25 According to a further aspect, the invention provides chimeric proteins which are obtained through conventional techniques by inserting the antiviral domains described above into proteins showing the desired biological characteristics.

Finally, the invention provides antiviral, antiinflammatory and antiallergic pharmaceutical compositions containing the above defined peptides or proteins as the active ingredient.

Preferred peptides of the invention have the following general formula
5 (I):

X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-
X18-X19-X20

wherein:

10 X1 = H, Ace, or any amino acid both N-acylated and non-acylated, or a dipeptide of sequence Y1-Y2 both N-acylated and non-acylated in which Y1 and Y2, are the same or different and represent any amino acid;

X2 = any hydrophobic amino acid;

X3 = Ala, Pro, Val, Thr, Ile, thioproline, hydroxyproline;

X4 = any hydrophobic amino acid;

15 X5 = any hydrophobic amino acid;

X6 = Ala, Pro, Val, Thr, Ile, thioproline, hydroxyproline;

X7 = any basic amino acid;

X8 = Pro, Val, Thr, Ile, thioproline, hydroxyproline;

X9 = Leu, Ile, Val, Thr, Chg, Cha;

20 X10 = Pro, Val, Thr, Ile, thioproline, hydroxyproline;

X11 = any basic amino acid;

X12 = Ala, Aib, Ser, Gly;

X13 = any basic amino acid;

X14 = any hydrophobic amino acid;

25 X15 = any basic amino acid;

X16 = any amino acid;

X17 = any hydrophobic amino acid;

X18 = any hydrophobic amino acid;

X19 = any hydrophobic amino acid;

X20 = OH, NH₂, Gly, or any hydrophobic amino acid.

Particularly preferred are compounds wherein:

5 X1 = H, Ace, Gly, Phe, Cha, Tyr, 1Nal, 2Nal, Trp, Asn, Cys, Ace-Cys, or a dipeptide of sequence Y1-Y2, both N-acylated and non-acylated, wherein Y1 and Y2 are the same or different and represent any amino acid;

X2 = Phe, Cha, Tyr, 1Nal, 2Nal, Trp;

X3 = Ala, Pro, Val, Thr, Ile;

X4 = Tyr, Phe, Cha, 1Nal, 2Nal, Trp;

10 X5 = Ile, Leu, Val, Thr, 1Nal, 2Nal, Phe, Tyr, Trp;

X6 = Ala, Pro, Val, Thr, Ile;

X7 = Lys, Arg, His, Orn, Dab, Dap, Pba;

X8 = Pro, Val, Thr, Ile;

X9 = Leu, Ile, Val, Thr, Chg, Cha;

15 X10 = Pro, Val, Thr, Ile;

X11 = Lys, Arg, His, Orn, Dab, Dap, Pba;

X12 = Ala, Aib, Ser, Gly;

X13 = Lys, Arg, His, Orn, Dab, Dap, Pba;

X14 = Ile, Phe, Tyr, Trp, 1Nal, 2Nal, Cha, Leu;

20 X15 = Lys, Arg, His, Orn, Dab, Dap, Pba;

X16 = any amino acid;

X17 = Tyr, Ile, Phe, Trp, 1Nal, 2Nal, Cha, Leu;

X18 = Phe, Ile, Tyr, Trp, 1Nal, 2Nal, Cha, Leu;

X19 = Tyr, Ile, Phe, Trp, 1Nal, 2Nal, Cha, Leu;

25 X20 = OH, NH₂, Gly, Phe, Tyr, Trp, 1Nal, 2Nal.

Further particularly preferred peptides are those wherein:

X1 = H, Ace, Cys, Ace-Cys;

X2 = Phe, Cha, Tyr;

X3 = Ala, Pro;

X4 = Tyr, Phe, Cha;

X5 = Ile, Leu, Val;

X6 = Ala, Pro, Val;

5 X7 = Lys, Arg, His, Orn;

X8 = Pro, Val;

X9 = Leu, Ile;

X10 = Pro, Val;

X11 = Lys, Arg, His, Orn;

10 X12 = Ala, Aib, Ser, Gly;

X13 = Lys, Arg, His, Orn;

X14 = Ile, Phe, Tyr, Trp, Cha, Leu;

X15 = Lys, Arg, Orn, Dab, Dap, Pba;

X16 = Glu, Asp;

15 X17 = Tyr, Ile, Phe, Trp, 1Nal, 2Nal;

X18 = Phe, Ile, Tyr, Trp, 1Nal, 2Nal, Leu;

X19 = Tyr, Ile, Phe, 1Nal, 2Nal, Cha, Leu;

X20 = OH, NH₂, Gly, Phe, Tyr, Trp.

20 The above amino acid belong to the L or D isomers of both natural amino acids and "non-proteic" amino acids conventionally used in peptide synthesis for the preparation of synthetic analogues of natural peptides. α -Amino acids substituted and non-substituted at the α and β positions of both L and D configuration and α - β unsaturated amino acids are indicated among the non-proteic amino acids.

25 The natural amino acids are glycine, alanine, valine, leucine, isoleucine, serine, methionine, threonine, phenylalanine, tyrosine, tryptophan, cysteine, proline, histidine, aspartic acid, asparagine, glutamic acid, glutamine, γ -carboxyglutamic acid, arginine, ornithine, lysine.

Examples of "non-proteic" amino acids are norleucine, norvaline, alloisoleucine, naphthyl-alanine (1Nal), 2-naphthyl-alanine (2Nal) allothreonine, homoarginine, thioproline, dehydroproline, hydroxyproline, pipercolic acid, azetidinic acid, homoserine, cyclohexylglycine (Chg), α -amino-n-butyric acid (Aba), cyclohexylalanine (Cha), aminophenylbutyric acid (Pba), phenylalanines mono- and di- substituted at the ortho, meta and para positions of the aromatic ring with one or more of the following groups: β -2- and 3-thienylalanine, β -2- and 3-furanylalanine, β -2-, 3- and 4-pyridylalanine, β -(1- or 2- naphthyl)alanine, serine, threonine and tyrosine O-alkylated derivatives, S-alkylated cysteine, S-alkylated homocysteine, ϵ -alkylated lysine, δ -alkylated ornithine, α,α -dimethylglycine (Aib), α -aminocyclopropane-carboxylic acid (Ac₃c), α -aminocyclobutanecarboxylic acid (Ac₄c), α -aminocyclopentanecarboxylic acid (Ac₅c), α -aminocyclohexanecarboxylic acid (Ac₆c), diethylglycine (Deg), dipropylglycine (Dpg), diphenylglycine (Dph), dehydroalanine (δ -Ala), dehydrotyrosine (δ -Tyr) and dehydroleucine (δ -Leu), β -alanine (β -Ala), 2,3-diaminopropionic acid (Dap). Other non-proteic amino acids are those described in: "Diversity of Synthetic Peptides", Konishi et al., First International Peptide Symposium, Kyoto, Japan, 1997.

Examples of hydrophobic amino acids, both natural and non-natural, of L or D configuration, are: glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tyrosine, tryptophan, proline, norleucine, norvaline, alloisoleucine, allothreonine, thioproline, dehydroproline, pipercolic acid, azetidinic acid, cyclohexylglycine (Chg), α -amino-n-butyric acid (Aba), cyclohexylalanine (Cha), phenylalanines mono- and di-substituted at the ortho, meta and para positions of the aromatic ring with one or more of the following groups: β -2- and 3-thienylalanine, β -2- and 3-furanylalanine, β -2-, 3- and 4-pyridylalanine, β -(1- or 2- naphthyl)alanine,

serine, threonine and tyrosine O-alkylated derivatives, S-alkylated cysteine, S-alkylated homocysteine, ϵ -alkylated lysine, δ -alkylated ornithine, α,α -dimethylglycine (Aib), α -aminocyclopropanecarboxylic acid (Ac_3c), α -aminocyclobutanecarboxylic acid (Ac_4c), α -aminocyclopentanecarboxylic acid (Ac_5c), α -aminocyclohexanecarboxylic acid (Ac_6c), diethylglycine (Deg), dipropylglycine (Dpg), diphenylglycine (Dph), dehydroalanine (δ -Ala), dehydroleucine (δ -Leu). Other non-proteic amino acids are those described in: "Diversity of Synthetic Peptides", Konishi et al., First International Peptide Symposium, Kyoto, Japan, 1997.

Examples of basic amino acids, both natural and non-natural, of L or D configuration, are: histidine, arginine, ornithine, lysine, aminophenylbutyric acid (Pba), ϵ -alkylated lysine, δ -alkylated ornithine, 2,3-diaminopropionic acid (Dap), 2,4-diaminobutyric acid (Dab). Other non-proteic amino acids are those described in: "Diversity of Synthetic Peptides", Konishi et al., First International Peptide Symposium, Kyoto, Japan, 1997.

The compounds of general formula I can also be used in combination with suitable counterions, as far as they are compatible with the specific applications.

The compounds of the invention can be synthesized with the various techniques known in literature, see for example Schroeder et al., "The Peptides" vol 1, Academic Press, 1965; Bodanszky et al., "Peptide Synthesis" Interscience Publisher, 1966; Barany & Merrifield, "The peptides; Analysis, Synthesis, Biology", 2, Chapter 1, Academic Press, 1980. These techniques include peptide synthesis in solid phase, peptide synthesis in solution, organic chemistry synthetic procedures, or any combination thereof. The selected synthetic scheme will of course depend on the composition of the specific molecule.

Preferably, synthetic procedures based on appropriate combinations of

techniques in solid phase and of conventional methods in solution will be used, which involve low production costs particularly on the industrial scale.

In more detail, said procedures consist of:

5 i) Synthesis in solution of fragments of the peptide chain through the successive coupling of N-protected amino acids, suitably activated, with an amino acid or a C-protected peptide chain, recovery of the intermediates, successive selective deprotection of the N and C-terminus of said fragments and coupling of them until obtaining the desired peptide. Finally, when necessary, the
10 side chains are deprotected.

ii) Synthesis in solid phase of the peptide chain from the C-terminus towards the N-terminus on an insoluble polymeric support. The peptide is removed from the resin by hydrolysis with anhydrous hydrofluoric acid or with trifluoroacetic acid in the presence of suitable scavengers,
15 with the concomitant deprotection of the side chains.

Particularly preferred sequences are the following:

1. Ace-FAYIARPLPRAHIKEYFY- NH₂
2. Ace-CFAYIARPLPRAHIKEYFY- NH₂
3. FAYIARPLPRAHIKEYFY- NH₂
- 20 4. CFAYIARPLPRAHIKEYFY- NH₂
5. CFAYIARPLPRAHIKEYFY- NH₂

|

CFAYIARPLPRAHIKEYFY- NH₂

6. Ace-YFYEKIHARPLPRAIYAFC-NH₂
- 25 7. YFYEKIHARPLPRAIYAFC-NH₂

|

YFYEKIHARPLPRAIYAFC-NH₂

8. FAYIARPLPRAHIKEYF- NH₂

9. AYIARPLPRAHIKEY- NH₂
10. CFAYIARPLPRAHIK- NH₂
11. CFAYIARPLPRAHIKE- NH₂
12. FAYIARPLPRAHIK- NH₂
- 5 13. PCCFAYIARPLPRAHIKE- NH₂
14. YIARPLPRAHIKEYFYTS- NH₂
15. CFAYIARPLPRAH- NH₂
16. CFAYIARPLPRA- NH₂
17. FAYIARPLPRAH- NH₂
- 10 18. CCFAYIARPLPRAHIKEY- NH₂
19. CFAYIARPLPRAHIKEYFYTSGKC

|_____|

The sequences N° 1,2, 5 and 6 are particularly preferred.

The amino acids of peptide N° 6 preferably belong to the D series.

- 15 Said sequences and peptides can be inserted in or bound to sequences of physiological proteins which act as non-toxic carriers for the antiviral domain, more specifically HIV-suppressive.

Examples of physiological proteins are human albumin or the fragment Fc γ of human immunoglobuline IgG.

- 20 The NH₂ and COOH terminus can be functionalized so as to make the peptides more resistant to proteases, or the peptides can be cyclized.

- 25 Some peptides of the invention have been tested to verify their inhibitory activity against HIV virus-1. Two different tests have been used: the "cell-free" acute infection test and the test of inhibition of the formation of syncytia. The first test evaluates the growth of HIV-1 in primary mononuclear cells pre-activated in vitro and is closer to the natural model of infection. On the other hand, the test of syncytia inhibition evaluates the

capability of an inhibitor to inhibit the membrane fusion induced by HIV and it makes use of cells of a continuous line T CD4+ (PM1) chronically infected with an HIV-1 CCR5-dependent (PM1BaL) strain. In both tests, cells were pre-treated with the peptides before exposition to the virus or to the infected cells. Scalar concentrations for each peptide have been tested to calculate the 50% inhibitory dose (ID₅₀), i.e. the dose capable of reducing by 50% the values of the untreated controls. The ID₅₀ values (expressed as micromolar values) of different peptides in the acute infection test are illustrated in the following Table:

10

Table

No.	Region	Peptide sequence	ID ₅₀
A	RANTES Y27-A38	YFYTSGKCSNPA	>150
B	RANTES Y29-V40	YTSGKCSNPAVV	>150
C	RANTES S31-V42	SGKCSNPAVVFV	>150
1	*ac-RANTES F12-Y29-am*	Ace-FAYIARPLPRAHIKEYFY-NH ₂	11
2	*ac-RANTES C11-Y29-am*	Ace-CFAYIARPLPRAHIKEYFY-NH ₂	9
3	RANTES C11-C34 (cyclic)	CFAYIARPLPRAHIKEYFYTSGKC _____	33

* Ac" indicates the acetylation of the N-terminus amino acid; "am" the amidation of the C-terminus amino acid.

As it can be seen in the Table, the two peptides ac-RANTES F12-Y29-am and ac-RANTES C11-Y29-am (n. 1-2) showed a marked increase in the capability to inhibit the acute infection by CCR5-dependent HIV-1BaL strain (i.e. a lower ID₅₀). Other peptides of RANTES, used as controls (A, B, C), showed no antiviral activity at the tested doses. Conversely, a cyclic peptide RANTES C11-C34 showed a good inhibitory activity. According to what observed in the acute infection test, the peptides n. 1 and 2 also

showed an increased capability to inhibit the formation of syncytia in the system of the PM1 line infected by HIV-1BaL.

The peptides of the invention are not capable of inducing activation of the CCR-5 receptor and therefore they induce no toxic pro-inflammatory effects.

The peptides of the invention, the derivatives thereof, or the chimeric proteins in which they are contained, can be used for the therapy or the prophylaxis of AIDS and of other diseases which are caused by the infection of primate lentiretrovirus and of other viruses which use chemokine receptors as membrane receptors. The peptides of the invention can be used for the treatment of allergic or autoimmune diseases, or for the treatment of any other disease in the pathogenesis and clinical manifestations of which the chemokines are involved. The peptides of the invention will be administered suitably formulated in pharmaceutical compositions, for example as reported in "Remington's Pharmaceutical Sciences Handbook", Mack Publishing Company, New York, U.S.A..

The compositions of the invention will contain an effective amount of the peptides (or the derivatives thereof and the chimeric proteins), for instance from 0.1 to 100 mg of peptide, and they will be administered preferably by the parenteral route, in particular by the subcutaneous or intramuscular routes. The daily amount will obviously depend on different factors, like severity of the disease, weight, sex and age of the patient, and it will be determined on the basis of the toxicological, pharmacokinetic and pharmacodynamic properties of each single peptide or derivative thereof.

Generally the peptide daily dosage will be comprised between 10 and 1500 μmol per Kg of body weight and the treatment will be maintained for a long time. Also other administration routes can be used, for example the oral route using liposome formulations or other techniques known for the

administration of peptides or proteins by the gastro-enteric route, as described in W093/25583.

Further, the peptides of the invention can be used for the production of anti-peptide antibodies and antiidiotype antibodies raised to the anti-peptide antibody, which anti-idiotype antibodies simulate the original peptide through their active site; for the development of peptide mimetics with antiviral activity or for the development of antagonists of the chemokine receptor.

Such antibodies, optionally human antibodies, have a favourable diffusion and stability and a longer half life in vivo.

The techniques used for the production of antiidiotype antibodies and human antibodies are described for example in W0 86/1539 and in EP-A-481790.

The peptides of the invention are useful also as diagnostic and research tools, for instance for the structural characterization of the active site by means of computer aided-molecular design, crystallography or NMR.

The following examples illustrate the invention in greater details.

EXAMPLE 1

Synthesis of the peptide

Ace-Phe-Ala-Tyr-Ile-Ala-Arg-Pro-Leu-Pro-Arg-Ala-His-Ile-Lys-Glu-Tyr-Phe-Tyr-NH₂,

corresponding to the compound of general formula (I) wherein: X1 = Ace; X2 = Phe; X3 = Ala; X4 = Tyr; X5 = Ile; X6 = Ala; X7 = Arg; X8 = Pro; X9 = Leu; X10 = Pro; X11 = Arg; X12 = Ala; X13 = His; X14 = Ile; X15 = Lys; X16 = Glu; X17 = Tyr; X18 = Phe; X19 = Tyr; X20 = NH₂.

This compound was prepared by peptide synthesis in solid phase. In particular, the methodology which makes use of the α -amino-protecting Fmoc group. Furthermore, said synthesis was carried out using an automatic

peptides synthesizer which operates in continuous flow. The synthesis was carried out using a solid support which provides the peptide as C-terminus amide. A 0.2 mmol synthetic scale was made use of, using a resin substitution equivalent to 0.50 mmol/g. The α -amino-protecting Fmoc group of each residue, after coupling, was removed by means of a 20% by volume solution of piperidine in DMF. Two successive treatments of 3 and 7 minutes, respectively, were used for each cycle. Amino acids have been bound in successive steps, and the conditions and the methodologies used for each single residue are those conventionally used in this synthesis.

After completion of the synthesis the N-terminus was acetylated by treatment with a 20% by volume solution of acetic anhydride in DMF. 10 ml of said solution were used and the treatment was carried out for 20 minutes. The peptide was removed from the resin simultaneously with the side chain protecting groups, by means of an ethanedithiol/anisole/TFA mixture in a 0.25/0.25/9.5 ratio (by volume) at 0°C for 2 h. The resin was filtered, and the crude peptide was precipitated from the acidic solution with ethyl ether. 0.193 g of crude product were obtained in the form of powder. A 42% yield was obtained, based on the resin substitution degree. The homogeneity of the product was evaluated by analytical HPLC, and it showed a single main peak at $t_r = 16.5$. The crude material was purified by preparative RP-HPLC. 0.038 g of pure product were obtained. The analytical HPLC confirmed the purity of the product. The identity of the product was confirmed by MALDI-TOF mass spectrometry, which confirmed the expected molecular weight of 2294 uma.

EXAMPLE 2

According to the same method of example 1, the following peptides were obtained:

a) Ace-CFAYIARPLPRAHIKEYFY; MW = 2400 Assay > 95%

b) Ace-YFYEKIHARPLPRAIYAFC; MW = 2400 Assay > 95%

Peptide b) consists of D-amino acids and its sequence corresponds to the inverted sequence of peptide a).

EXAMPLE 3

5 Inhibition of the viral infection

The ability of the mutants obtained as described in Example 2, to inhibit the infection by the prototypic macrophage-tropic HIV-1BaL strain, was evaluated in primary cultures of activated mononuclear cells from peripheral blood. The procedure used to infect PBL and to evaluate the
10 production of p24 antigen is described in literature (Scarlati et al., Nat. Med. Nov. 3:11 1259-65, 1997).

CLAIMS

1. Peptides having 12 to 30 amino acids with sequence identical to a portion of at least 5 consecutive aminoacids of the sequence 9-38 of RANTES as well as derivatives thereof obtainable by substituting the natural amino acid with the corresponding amino acid of the D series or with non-protein amino acid and/or by inverting the sequence from the carboxy-terminus to the N-terminus and/or by forming dimers through cysteine disulfide bonds and/or by single deletion of amino acids of the native sequence or peptides having two or more of the above characteristics sequences or domains linked by a suitable linker.

2. Peptides according to claim 1 having from 15 to 35 amino acids.

3. Peptides according to claim 2 having from 18 to 25 amino acids.

4. Peptides according to any one of claims 1 to 3 having a sequence derived from or identical to at least 10 consecutive amino acids of the sequence 9-38 of RANTES, the other amino acids in the peptide sequence deriving from conservative substitutions of the natural amino acids in the native sequence of RANTES.

5. Peptides according to any one of claims 1 to 4 functionalized at the N- or C-terminus.

6. Peptides according to claim 1 of formula:

X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18-X19-X20

X1 = H, Ace, or any amino acid both N-acylated and non-acylated, or a dipeptide of sequence Y1-Y2 both N-acylated and non-acylated in which Y1 and Y2, are the same or different and represent any amino acid;

X2 = any hydrophobic amino acid;

X3 = Ala, Pro, Val, Thr, Ile, thioproline, hydroxyproline;

X4 = any hydrophobic amino acid;

X5 = any hydrophobic amino acid;

X6 = Ala, Pro, Val, Thr, Ile, thioproline, hydroxyproline;

X7 = any basic amino acid;

5 X8 = Pro, Val, Thr, Ile, thioproline, hydroxyproline;

X9 = Leu, Ile, Val, Thr, Chg, Cha;

X10 = Pro, Val, Thr, Ile, thioproline, hydroxyproline;

X11 = any basic amino acid;

X12 = Ala, Aib, Ser, Gly;

10 X13 = any basic amino acid;

X14 = any hydrophobic amino acid;

X15 = any basic amino acid;

X16 = any amino acid;

X17 = any hydrophobic amino acid;

15 X18 = any hydrophobic amino acid;

X19 = any hydrophobic amino acid;

X20 = OH, NH₂, Gly, or any hydrophobic amino acid.

7. Peptides according to claim 4 wherein:

20 X1 = H, Ace, Gly, Phe, Cha, Tyr, 1Nal, 2Nal, Trp, Asn, Cys, Ace-Cys, or a dipeptide of sequence Y1-Y2 both N-acylated and non-acylated wherein Y1 and Y2, are the same or different and represent any amino acid;

X2 = Phe, Cha, Tyr, 1Nal, 2Nal, Trp;

X3 = Ala, Pro, Val, Thr, Ile;

X4 = Tyr, Phe, Cha, 1Nal, 2Nal, Trp;

25 X5 = Ile, Leu, Val, Thr, 1Nal, 2Nal, Phe, Tyr, Trp;

X6 = Ala, Pro, Val, Thr, Ile;

X7 = Lys, Arg, His, Orn, Dab, Dap, Pba;

X8 = Pro, Val, Thr, Ile;

X9 = Leu, Ile, Val, Thr, Chg, Cha;

X10 = Pro, Val, Thr, Ile;

X11 = Lys, Arg, His, Orn, Dab, Dap, Pba;

X12 = Ala, Aib, Ser, Gly;

5 X13 = Lys, Arg, His, Orn, Dab, Dap, Pba;

X14 = Ile, Phe, Tyr, Trp, 1Nal, 2Nal, Cha, Leu;

X15 = Lys, Arg, His, Orn, Dab, Dap, Pba;

X16 = any amino acid;

X17 = Tyr, Ile, Phe, Trp, 1Nal, 2Nal, Cha, Leu;

10 X18 = Phe, Ile, Tyr, Trp, 1Nal, 2Nal, Cha, Leu;

X19 = Tyr, Ile, Phe, Trp, 1Nal, 2Nal, Cha, Leu;

X20 = OH, NH₂, Gly, Phe, Tyr, Trp, 1Nal, 2Nal.

8. Peptides according to claim 7 wherein:

X1 = H, Ace, Cys, Ace-Cys;

15 X2 = Phe, Cha, Tyr;

X3 = Ala, Pro;

X4 = Tyr, Phe, Cha;

X5 = Ile, Leu, Val;

X6 = Ala, Pro, Val;

20 X7 = Lys, Arg, His, Orn;

X8 = Pro, Val;

X9 = Leu, Ile;

X10 = Pro, Val;

X11 = Lys, Arg, His, Orn;

25 X12 = Ala, Aib, Ser, Gly;

X13 = Lys, Arg, His, Orn;

X14 = Ile, Phe, Tyr, Trp, Cha, Leu;

X15 = Lys, Arg, Orn, Dab, Dap, Pba;

X16 = Glu, Asp;

X17 = Tyr, Ile, Phe, Trp, 1Nal, 2Nal;

X18 = Phe, Ile, Tyr, Trp, 1Nal, 2Nal, Leu;

X19 = Tyr, Ile, Phe, 1Nal, 2Nal, Cha, Leu;

5 X20 = OH, NH₂, Gly, Phe, Tyr, Trp.

9. Peptides according to claim 1 having the sequences

1. Ace-FAYIARPLPRAHIKEYFY- NH₂

2. Ace-CFAYIARPLPRAHIKEYFY- NH₂

3. FAYIARPLPRAHIKEYFY- NH₂

10 4. CFAYIARPLPRAHIKEYFY- NH₂

5. CFAYIARPLPRAHIKEYFY- NH₂

|

CFAYIARPLPRAHIKEYFY- NH₂

6. Ace-YFYEKIHARPLPRAIYAFC-NH₂

15 7. YFYEKIHARPLPRAIYAFC-NH₂

|

YFYEKIHARPLPRAIYAFC-NH₂

8. FAYIARPLPRAHIKEYF- NH₂

9. AYIARPLPRAHIKEY- NH₂

20 10. CFAYIARPLPRAHIK- NH₂

11. CFAYIARPLPRAHIKE- NH₂

12. FAYIARPLPRAHIK- NH₂

13. PCCFAYIARPLPRAHIKE- NH₂

14. YIARPLPRAHIKEYFYTS- NH₂

25 15. CFAYIARPLPRAH- NH₂

16. CFAYIARPLPRA- NH₂

17. FAYIARPLPRAH- NH₂

18. CCFAYIARPLPRAHIKEY- NH₂

19. CFAYIARPLPRAHIKEYFYTSGKC

10. Chimeric proteins which are obtained through conventional techniques by inserting the peptides of claims 1-9, into proteins showing the desired biological characteristics.

11. Compositions pharmaceutical containing as active principle the peptides of claims 1-9.

12. Vaccines containing a peptide of claims 1-9.

13. The use of the peptides of claims 1-9 for the preparation of anti-HIV medicaments.

14. The use of peptides of claims 1-9 for the preparation of medicaments for the treatment of allergic or autoimmune diseases, or for the treatment of any other disease in the pathogenesis and clinical manifestations of which the chemokines are involved.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 14/52, A61K 38/19, A61P 37/00	A3	(11) International Publication Number: WO 00/27880 (43) International Publication Date: 18 May 2000 (18.05.00)
(21) International Application Number: PCT/EP99/08651 (22) International Filing Date: 11 November 1999 (11.11.99) (30) Priority Data: MI98A002441 11 November 1998 (11.11.98) IT (71) Applicants (for all designated States except US): FON- DAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR [IT/IT]; Via Olgettina, 60, I-20132 Milano (IT). PRIMM S.R.L. [IT/IT]; Via Olgettina, 58, I-20132 Milano (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): LUSSO, Paolo [IT/IT]; Via Olgettina, 58, I-20132 Milano (IT). PAVONE, Vin- cenzo [IT/IT]; Viale Michelangelo, 52, I-80129 Napoli (IT). (74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 5 October 2000 (05.10.00)
(54) Title: RANTES-DERIVED PEPTIDES WITH ANTI-HIV ACTIVITY (57) Abstract Peptides having 12 to 30 amino acids with sequence homologous or corresponding to the sequence 10-34 of RANTES having inhibitory activity against the human immunodeficiency virus (HIV) as well as anti-allergic and antiinflammatory activity.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/EP 99/08651

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/52 A61K38/19 A61P37/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 98 51705 A (LUSSO PAOLO ; FONDAZIONE CENTRO SAN RAFFAELE (IT)) 19 November 1998 (1998-11-19) page 6, line 30 - page 7, line 8; claims	1-8, 10-14
P, X	WO 99 11666 A (GRYPHON SCIENCES) 11 March 1999 (1999-03-11) example 1	1, 2
A	WO 97 19696 A (LUSSO PAOLO ; GALLO ROBERT C (US); COCCHI FIORENZA (US); VICO ANTHO) 5 June 1997 (1997-06-05) claims; examples	1, 11, 13

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

19 June 2000

Date of mailing of the international search report

27/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Fuhr, C

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/08651

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9851705	A	19-11-1998	IT MI971105 A AU 8016398 A	12-11-1998 08-12-1998
WO 9911666	A	11-03-1999	AU 9215798 A	22-03-1999
WO 9719696	A	05-06-1997	AU 1141997 A EP 0869812 A	19-06-1997 14-10-1998

Form PCT/ISA/210 (patent family annex) (July 1992)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.